Search results for "modelling."

showing 10 items of 1269 documents

Increased expression of interleukin-22 in patients with giant cell arteritis

2017

Objectives GCA is characterized by arterial remodelling driven by inflammation. IL-22 is an attractive cytokine which acts at the crosstalk between immune and stromal cells. We hypothesized that IL-22 might be induced in GCA and might be involved in disease pathogenesis. Methods Patients subjected to temporal artery biopsies (TABs) naive from therapy were enrolled: 27 biopsy-proven GCA, 8 biopsy-negative GCA, 21 biopsy-negative non-GCA patients. Expression of IL-22 was determined in TABs by immunohystochemistry, in plasma by ELISA, in peripheral blood mononuclear cells by real-time PCR and flow cytometry. Effects of IL-22 on viability and gene expression of primary cultures obtained from TA…

0301 basic medicineCD4-Positive T-LymphocytesMalearterial remodelling; autoimmunity; giant cell arteritis; inflammation; interleukin-22; pathogenesismedicine.medical_treatmentMessengerInterleukin 220302 clinical medicineimmune system diseasesarterial remodelling; autoimmunity; giant cell arteritis; inflammation; interleukin-22; pathogenesis; Aged; Aged 80 and over; CD4-Positive T-Lymphocytes; Calcium Ionophores; Carcinogens; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Giant Cell Arteritis; Humans; Immunohistochemistry; In Vitro Techniques; Interleukins; Ionomycin; Leukocytes Mononuclear; Male; RNA Messenger; Real-Time Polymerase Chain Reaction; Temporal Arteries; Tetradecanoylphorbol Acetate80 and overLeukocytesPharmacology (medical)skin and connective tissue diseasesAged 80 and overIonomycinpathogenesisautoimmunityInterleukinFlow CytometryImmunohistochemistryTemporal ArteriesCalcium IonophoresCytokinecardiovascular systemTetradecanoylphorbol AcetateFemalemedicine.symptomgiant cell arteritiStromal cellMononuclearGiant Cell ArteritisInflammationEnzyme-Linked Immunosorbent AssayIn Vitro TechniquesReal-Time Polymerase Chain ReactionPeripheral blood mononuclear cellarterial remodelling03 medical and health sciencesRheumatologymedicineHumansViability assayRNA Messengercardiovascular diseasesAged030203 arthritis & rheumatologybusiness.industryInterleukinsinterleukin-22medicine.diseaseGiant cell arteritis030104 developmental biologyinflammationCase-Control StudiesImmunologyCarcinogensLeukocytes MononuclearRNAbusiness
researchProduct

Improving risk assessments in conservation ecology

2019

Conservation efforts and management decisions on the living environment of our planet often rely on the results from statistical models. Yet, these models are imperfect and quantification of risk associated with the estimate of management-relevant quantities becomes crucial in providing robust advice. Here we demonstrate that estimates of risk themselves could be substantially biased but by combining data fitting with an extensive simulation–estimation procedure, one can back-calculate the correct values. We apply the method to 627 time series of population abundance across four taxa using the Gompertz state-space model as an example. We find that the risk of large bias in population status…

0301 basic medicineConservation of Natural ResourcesComputer scienceLiving environmentScienceGompertz functionPopulation DynamicsGeneral Physics and Astronomy02 engineering and technologyRisk AssessmentGeneral Biochemistry Genetics and Molecular BiologyArticle03 medical and health sciencesEconometricsAnimalsHumanslcsh:ScienceEcological modellingPopulation DensityMultidisciplinaryModels StatisticalEcologyConservation biologyQStatistical modelGeneral ChemistryVDP::Matematikk og Naturvitenskap: 400Biodiversity021001 nanoscience & nanotechnologyPopulation abundancePopulation variabilityEnvironmental sciences030104 developmental biologyDensity dependencelcsh:QConservation ecology0210 nano-technologyRisk assessmentNature Communications
researchProduct

Design, synthesis and preliminary evaluation of dopamine-amino acid conjugates as potential D1 dopaminergic modulators.

2016

Abstract The dopamine-amino acid conjugate DA-Phen was firstly designed to obtain a useful prodrug for the therapy of Parkinson's disease, but experimental evidence shows that it effectively interacts with D1 dopamine receptors (D1DRs), leading to an enhancement in cognitive flexibility and to the development of adaptive strategies in aversive mazes, together with a decrease in despair-like behavior. In this paper, homology modelling, molecular dynamics, and site mapping of D1 receptor were carried out with the aim of further performing docking studies on other dopamine conjugates compared with D1 agonists, in the attempt to identify new compounds with potential dopaminergic activity. Two n…

0301 basic medicineDopamineDopamine AgentsChemistry Techniques SyntheticPharmacology01 natural sciencesDocking03 medical and health sciencesDopamine receptor D1Drug StabilityDopamineCatalytic DomainDrug DiscoverymedicineAnimalsHumansAmino Acidschemistry.chemical_classificationConjugatePharmacologyPCA010405 organic chemistryChemistrySynthesiDrug Discovery3003 Pharmaceutical ScienceReceptors Dopamine D1DopaminergicOrganic ChemistryBrainGeneral MedicineProdrug0104 chemical sciencesAmino acidAmino acidRatsMolecular Docking Simulation030104 developmental biologyBiochemistryDocking (molecular)Dopamine receptorDrug DesignMolecular modellingConjugatemedicine.drugEuropean journal of medicinal chemistry
researchProduct

A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC …

2019

Drug-induced liver injury (DILI) is a matter of concern in the course of drug development and patient safety, often leading to discontinuation of drug-development programs or early withdrawal of drugs from market. Hepatocellular toxicity or impairment of bile acid (BA) metabolism, known as cholestasis, are the two clinical forms of DILI. Whole-body physiology-based modelling allows a mechanistic investigation of the physiological processes leading to cholestasis in man. Objectives of the present study were: (1) the development of a physiology-based model of the human BA metabolism, (2) population-based model validation and characterisation, and (3) the prediction and quantification of alter…

0301 basic medicineEXPRESSIONPBPKLIVERmedicine.drug_classPhysiologyBenign Recurrent Intrahepatic CholestasisPopulationBIOMARKERScomputational modellingPhysiologyDIAGNOSISlcsh:Physiology03 medical and health scienceschemistry.chemical_compoundPHARMACOKINETIC MODEL0302 clinical medicineCholestasisPhysiology (medical)Glycochenodeoxycholic acidMedicineddc:610educationEnterohepatic circulationKINETICSOriginal ResearchLiver injuryINTRAHEPATIC CHOLESTASISbile acidseducation.field_of_studyBile acidlcsh:QP1-981business.industryBRIC type 2medicine.diseaseTRANSPORTERS3. Good health030104 developmental biologychemistryToxicitySIMULATION030211 gastroenterology & hepatologyENTEROHEPATIC CIRCULATIONDILIbusinesscholestasisFrontiers in Physiology
researchProduct

Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015

2020

The incidence of vulvar squamous cell carcinoma has increased for decades in most Western countries - a trend virtually restricted to women aged50 or 60 years. In southern Europe, conversely, the trends have been insufficiently studied. This article reports a study from Italy.Thirty-eight local cancer registries, currently covering 15,274,070 women, equivalent to 49.2% of the Italian national female population, participated. Invasive cancers registered between 1990 and 2015 with an International Classification of Diseases for Oncology, 3rd revision, topography code C51 and morphology codes compatible with vulvar squamous cell carcinoma (n = 6294) were eligible. Incidence trends were analyse…

0301 basic medicineHistoryVulvar Squamous Cell CarcinomaAge-period-cohort modelling; Incidence; Trend; Vulvar neoplasms; Carcinoma Squamous Cell; Female; History 20th Century; History 21st Century; Humans; Incidence; Italy; Middle Aged; Vulvar NeoplasmsSettore MED/42 - Igiene Generale E ApplicataHistory 21st CenturyNO03 medical and health sciences0302 clinical medicineAge-period-cohort modellingAge-period-cohort modelling; Incidence; Trend; Vulvar neoplasmsTrendHumansMedicineRisk factorVulvar neoplasmVulvar Neoplasmsbusiness.industryIncidenceIncidence (epidemiology)CarcinomaObstetrics and GynecologyHistory 20th CenturyMiddle Aged21st CenturyConfidence intervalCancer registry20th CenturyTrend analysis030104 developmental biologySquamous CellItalyOncology030220 oncology & carcinogenesisVulvar neoplasms incidence trend age-period-cohort modellingCarcinoma Squamous CellFemalebusinessDemographyCohort studyGynecologic Oncology
researchProduct

Metabolic complementation in bacterial communities: Necessary conditions and optimality

2016

Bacterial communities may display metabolic complementation, in which different members of the association partially contribute to the same biosynthetic pathway. In this way, the end product of the pathway is synthesized by the community as a whole. However, the emergence and the benefits of such complementation are poorly understood. Herein, we present a simple model to analyze the metabolic interactions among bacteria, including the host in the case of endosymbiotic bacteria. The model considers two cell populations, with both cell types encoding for the same linear biosynthetic pathway. We have found that, for metabolic complementation to emerge as an optimal strategy, both product inhib…

0301 basic medicineMicrobiology (medical)Cell typeSystems biology030106 microbiologyCelllcsh:QR1-502Computational biologyBiologyMicrobiologylcsh:Microbiology03 medical and health sciencesMetabolic complementationmetabolic modelingHypothesis and TheoryBotanymedicineCinara cedricross-feedingEndosymbiotic bacteriaHost (biology)biology.organism_classificationkinetic modelingComplementation030104 developmental biologymedicine.anatomical_structureProduct inhibitionendosymbiotic bacteriaMetabolic ModellingoptimizationBacteria
researchProduct

PBRM1 loss is a late event during the development of cholangiocarcinoma

2017

Aims: Somatic mutations in genes encoding chromatin remodellers have been reported recently in several cancer types, including approximately half of cholangiocarcinomas. One of the most commonly mutated chromatin remodellers in cholangiocarcinoma is the Polybromo-1 (PBRM1) gene located on chromosome 3p21, which encodes a subunit of the SWI/SNF complex. The aim of this study was to determine the timing of PBRM1 mutations in biliary carcinogenesis. Methods and results: In order to accomplish this goal, we used immunohistochemistry to assess PBRM1 protein expression in a series of precursor lesions and invasive biliary carcinomas. Previous studies have correlated loss of protein expression on …

0301 basic medicinePathologymedicine.medical_specialtyHistologyBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodellingchromatin remodellingKaplan-Meier EstimateBiologymedicine.disease_causeArticleBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodelingChromatin remodelingchromatin remodelingPathology and Forensic MedicinePBRM1PBRM103 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansBilinIntrahepatic CholangiocarcinomaProportional Hazards ModelsBilINMutationNuclear ProteinsCancerGeneral MedicinePrognosismedicine.diseaseChromatinDNA-Binding Proteinsbiliary dysplasiaCell Transformation Neoplastic030104 developmental biologyBile Duct Neoplasmschemistry030220 oncology & carcinogenesisMutationCarcinogenesischolangiocarcinomaTranscription Factors
researchProduct

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients

2017

International audience; T lymphoblastic lymphoma (T-LBL) is a rare type of lymphoma with a good prognosis with a remission rate of 85%. Patients can be completely cured or can relapse during or after a 2-year treatment. Relapses usually occur early after the remission of the acute phase. The median time of relapse is equal to 1 year, after the occurrence of complete remission (range 0.2–5.9 years) (Uyttebroeck et al., 2008). It can be assumed that patients may be treated longer than necessary with undue toxicity. The aim of our model was to investigate whether the duration of the maintenance therapy could be reduced without increasing the risk of relapses and to determine the minimum treatm…

0301 basic medicinePediatricsmedicine.medical_specialtymedicine.medical_treatmentPopulation[SDV.CAN]Life Sciences [q-bio]/CancerPrecursor T-Cell Lymphoblastic Leukemia-LymphomachemotherapyGeneral Biochemistry Genetics and Molecular Biology[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences[ MATH.MATH-AP ] Mathematics [math]/Analysis of PDEs [math.AP][SDV.CAN] Life Sciences [q-bio]/CancerMaintenance therapythymusT-cell lymphoblastic lymphomamedicineHumanscancer[MATH.MATH-AP]Mathematics [math]/Analysis of PDEs [math.AP]Computer Simulationmathematical modelling[MATH.MATH-AP] Mathematics [math]/Analysis of PDEs [math.AP]educationrandomized controlled clinical trialGeneral Environmental SciencePharmacologyChemotherapyeducation.field_of_studyGeneral Immunology and Microbiologybusiness.industryApplied MathematicsGeneral NeuroscienceLymphoblastic lymphomaCancerGeneral MedicineModels Theoreticalmedicine.disease3. Good healthLymphomaSurgeryClinical trial030104 developmental biologyModeling and SimulationCohortDisease ProgressionbusinessMathematical Medicine and Biology
researchProduct

Impact of COVID-19 on global HCV elimination efforts.

2021

Background & Aims COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. Methods Previously developed models were adapted for 110 countries to include a status quo or “no delay” scenario and a “1-year delay” scenario assuming significant disruption in interventions (screening, diagnosis and …

0301 basic medicinePsychological interventioncoronavirusUMIC upper-middle income countriesGlobal HealthUI uncertainty intervalHIC high income countries0302 clinical medicineCost of IllnessLIC low income countriesMedicineUSA United States of AmericaLetter to the EditorMathematical modellingPWID people who inject drugsLiver DiseaseLiver DiseasesVaccinationmathematical modelingGBD Global Burden of DiseaseHepatitis CSVR sustained virologic responseEuropeHCV hepatitis C virusHepatocellular carcinomaHCVGHSS Global Health Sector StrategyRNA Viral030211 gastroenterology & hepatologyAMR region of the AmericasLiver cancerViral hepatitisHumanCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)EMR Eastern Mediterranean regionViral hepatitis eliminationviral hepatitisContext (language use)World Health OrganizationArticleWHO World Health OrganizationTime-to-Treatment03 medical and health scienceseliminationEnvironmental healthHumansLMIC lower-middle income countriesDisease EradicationDisease burdenHepatitisHepatologySARS-CoV-2business.industryWPR Western Pacific regionCOVID-19Models Theoreticalmedicine.diseaseCost of Illne030104 developmental biologySpainHCC hepatocellular carcinomabusinessJournal of hepatology
researchProduct

JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study

2018

BackgroundPulmonary hypertension (PH) is a common disorder in patients with idiopathic pulmonary fibrosis (IPF) and portends a poor prognosis. Recent studies using vasodilators approved for PH have failed in improving IPF mainly due to ventilation (V)/perfusion (Q) mismatching and oxygen desaturation. Janus kinase type 2 (JAK2) is a non-receptor tyrosine kinase activated by a broad spectrum of profibrotic and vasoactive mediators, but its role in PH associated to PH is unknown.ObjectiveThe study of JAK2 as potential target to treat PH in IPF.Methods and resultsJAK2 expression was increased in pulmonary arteries (PAs) from IPF (n=10; 1.93-fold; P=0.0011) and IPF+PH (n=9; 2.65-fold; P<0.00…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyHypertension PulmonaryBlotting WesternMyocytes Smooth MuscleFluorescent Antibody TechniqueVasodilationVascular RemodelingReal-Time Polymerase Chain ReactionVascular remodelling in the embryo03 medical and health sciencesIdiopathic pulmonary fibrosisTransforming Growth Factor betaRight ventricular hypertrophyInternal medicinepulmonary hypertensionAnimalsHumansMedicineRNA Small InterferingRats WistarCells CulturedCell ProliferationBKCaJanus kinase 2biologybusiness.industryEndothelial CellsJanus Kinase 2idiopathic pulmonary fibrosismedicine.diseaseImmunohistochemistryPulmonary hypertensionIdiopathic Pulmonary FibrosisTriterpenesRatsPhenotype030104 developmental biologyJAK2biology.proteinCardiologyAnimal studiesJanus kinasebusinessSignal TransductionPulmonary artery smooth muscle cells Pulmonary artery endothelial cells.Thorax
researchProduct